Emergent BioSolutions posts $110M revenue and $32.7M loss in latest quarter

what happened

According to a 10-Q summary published by TradingView, Emergent BioSolutions generated $110 million in revenue in the latest quarter, down 52.4% from $231.1 million a year earlier. The company posted a net loss of $32.7 million, compared with a profit of $51.2 million in the same period last year, and its diluted loss per share came to $0.64, against earnings of $0.91 previously.

Over the first nine months, revenue slid 16% to $500.4 million. The drop was driven mainly by weaker U.S. over-the-counter NARCAN sales and less favorable pricing in public-sector channels, while commercial product sales fell 26% year to date. Medical countermeasure sales declined 8%, and contracts and grants income dropped 47%.

An August restructuring cut about 90 jobs to lower costs, and the company expects these steps to be largely finished in the fourth quarter of 2026.

why it matters

Sharp declines across key product lines point to pressure on the company's financial results. The restructuring aims to trim costs, but dependence on NARCAN and government contracts remains a notable risk for Emergent BioSolutions shares and for investors in the biotech sector.

market impact

Emergent BioSolutions shares: falling revenue and a wider loss weigh on the stock

• ▼Emergent BioSolutions shares pressure down — revenue and profit fell sharply, widening the loss

tags

instruments